3.78
Mannkind Corp stock is traded at $3.78, with a volume of 2.06M.
It is down -2.33% in the last 24 hours and up +1.07% over the past month.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
See More
Previous Close:
$3.87
Open:
$3.87
24h Volume:
2.06M
Relative Volume:
0.81
Market Cap:
$1.15B
Revenue:
$248.37M
Net Income/Loss:
$11.74M
P/E Ratio:
75.60
EPS:
0.05
Net Cash Flow:
$18.24M
1W Performance:
-7.35%
1M Performance:
+1.07%
6M Performance:
-34.72%
1Y Performance:
-34.38%
Mannkind Corp Stock (MNKD) Company Profile
Name
Mannkind Corp
Sector
Industry
Phone
818-661-5000
Address
1 CASPER STREET, DANBURY, CA
Compare MNKD with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MNKD
Mannkind Corp
|
3.78 | 1.18B | 248.37M | 11.74M | 18.24M | 0.05 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-16-25 | Resumed | H.C. Wainwright | Buy |
Apr-10-25 | Initiated | Mizuho | Outperform |
Feb-10-25 | Initiated | Wedbush | Outperform |
Dec-20-24 | Initiated | Wells Fargo | Overweight |
Dec-19-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Sep-09-24 | Resumed | Leerink Partners | Outperform |
Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
Oct-10-23 | Initiated | Wedbush | Outperform |
May-14-21 | Initiated | RBC Capital Mkts | Sector Perform |
Dec-24-19 | Initiated | Oppenheimer | Outperform |
Oct-25-19 | Initiated | Cantor Fitzgerald | Overweight |
May-14-19 | Initiated | BTIG Research | Buy |
Mar-04-19 | Initiated | SVB Leerink | Outperform |
Feb-22-19 | Initiated | SVB Leerink | Outperform |
Feb-28-18 | Downgrade | Maxim Group | Hold → Sell |
Nov-01-17 | Downgrade | Maxim Group | Buy → Hold |
Oct-10-17 | Initiated | H.C. Wainwright | Buy |
Oct-06-17 | Reiterated | Maxim Group | Buy |
Aug-11-17 | Initiated | Maxim Group | Buy |
May-10-16 | Reiterated | Piper Jaffray | Underweight |
May-10-16 | Reiterated | RBC Capital Mkts | Underperform |
Jan-06-16 | Reiterated | Piper Jaffray | Underweight |
Jan-06-16 | Reiterated | RBC Capital Mkts | Underperform |
Nov-04-15 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
Sep-09-15 | Downgrade | Piper Jaffray | Neutral → Underweight |
Aug-03-15 | Reiterated | RBC Capital Mkts | Outperform |
May-11-15 | Downgrade | JP Morgan | Neutral → Underweight |
May-11-15 | Reiterated | MLV & Co | Hold |
Apr-16-15 | Reiterated | RBC Capital Mkts | Outperform |
View All
Mannkind Corp Stock (MNKD) Latest News
Wedbush Remains Bullish on MannKind Corporation (MNKD) - Insider Monkey
10 Penny Stocks That Will Skyrocket - Insider Monkey
MannKind Corporation to Release Second Quarter 2025 Financial Results and Host Webcast on August 6, 2025 - Quiver Quantitative
MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025 - Stock Titan
What makes MannKind Corporation stock price move sharplyMomentum Based Equity Trading Plans Reviewed - metal.it
AI Tools Suggest MannKind Corporation May Outperform This WeekChart Driven High Reward Trading Setup Presented - metal.it
Why is MannKind Corporation stock attracting strong analyst attentionFree Daily Trading Room Entry - jammulinksnews.com
How volatile is MannKind Corporation stock compared to the marketCapitalize on fast-moving stock opportunities - jammulinksnews.com
RBC Capital Lowered the PT on MannKind Corporation (MNKD), Kept a Buy Rating - Insider Monkey
How MannKind Corporation stock performs during market volatilityCapital Safe Smart Trades - metal.it
What drives MannKind Corporation stock priceFree Stock Selection - PrintWeekIndia
MannKind stock price target lowered to $8 at RBC Capital on model updates - Investing.com Canada
MannKind Corporation (MNKD) Presented Inhaled Insulin Therapy At American Diabetes Association - Insider Monkey
What analysts say about MannKind Corporation stockLightning-fast capital gains - jammulinksnews.com
11 Best American Penny Stocks to Buy According to Analysts - Insider Monkey
MannKind Corporation Stock Analysis and ForecastBreakthrough profits - jammulinksnews.com
MannKind (NASDAQ:MNKD) Upgraded at HC Wainwright - Defense World
Mannkind director Binder sells $296945 in shares By Investing.com - Investing.com India
Mannkind director Binder sells $296945 in shares - Investing.com
H.C. Wainwright assumes coverage on MannKind stock with Buy rating - Investing.com
Why MannKind Corporation stock attracts strong analyst attentionGrowth Stock Monitor - Newser
High Growth Tech Stocks To Watch In The US July 2025 - Yahoo Finance
Wells Fargo Maintains a Buy Rating on MannKind Corporation (MNKD), Sets a $9 PT - Insider Monkey
13 Best Healthcare Stocks to Buy Under $10 - Insider Monkey
13 Stocks Under $5 With High Upside Potential - Insider Monkey
MannKind Corp stock hits 52-week low at $3.63 - Investing.com
MannKind Corporation(NasdaqGM: MNKD) dropped from Russell 3000 Value Index - MarketScreener
Today In SCV History: June 27, 2014 – Valencia Company Given FDA Approval For Inhaled Insulin - KHTS Radio
Is Day One Biopharmaceuticals, Inc. overvalued or undervalued? - MarketsMojo
Leerink Partners Slashes MannKind Corporation’s (MNKD) Price Target to $7, Keeps a Buy Rating - Insider Monkey
13 Best Long-Term Penny Stocks to Buy According to Analysts - Insider Monkey
MannKind stock hits 52-week low at $3.70 - Investing.com
Top 3 Health Care Stocks That May Rocket Higher This Quarter - Benzinga
Insider Sell: Steven Binder Sells 64,085 Shares of MannKind Corp (MNKD) - GuruFocus
MannKind director Steven Binder sells $256,340 in shares By Investing.com - Investing.com South Africa
MannKind director Steven Binder sells $256,340 in shares - Investing.com Australia
Phase II home run: Insmed’s TPIP hits hypertension endpoints - BioWorld MedTech
MannKind stock touches 52-week low at $4.04 amid market shifts - Investing.com Nigeria
MannKind to present inhaled insulin study at ADA event By Investing.com - Investing.com Canada
MannKind to present inhaled insulin study at ADA event - Investing.com
Breakthrough in Pediatric Diabetes Care: MannKind Phase 3 Trial Data Reveals New Inhaled Insulin Treatment Option - Stock Titan
MannKind at Jefferies Global Healthcare: Strategic Growth and Innovation By Investing.com - Investing.com Canada
Mannkind Corp Stock (MNKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):